A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: rarely (96), occasionally (192), seldom (7)

InP RIVAC (66) cytarabine etoposide ifosfamide rituximab

Description
Chemotherapy Protocol LYMPHOMA CYTARABINE-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RIVAC) 66 years and above Inpatient Regimen There are multiple versions of this protocol in use. The choice of protocol depends
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RIVAC-66-cytarabine-etoposide-ifosfamide-rituximab.pdf

InP RIVAC (65) cytarabine etoposide ifosfamide rituximab

Description
Chemotherapy Protocol LYMPHOMA CYTARABINE-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RIVAC) 65 years and below Inpatient Regimen There are multiple versions of this protocol in use. The choice of protocol depends
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RIVAC-65-cytarabine-etoposide-ifosfamide-rituximab.pdf

DRC-Cyclophosphamide-Dexamethasone-Rituximab

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE - DEXAMETHASONE – RITUXIMAB (DRC) Regimen • Lymphoma – DRC – Cyclophosphamide – Dexamethasone - Rituximab Indication • Lymphophlasmacytic lymph
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/DRC-Cyclophosphamide-Dexamethasone-Rituximab.pdf

Bendamustine-Rituximab

Description
Chemotherapy Protocol LYMPHOMA BENDAMUSTINE-RITUXIMAB There are multiple versions of this protocol in use. Pleas
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Bendamustine-Rituximab.pdf

Bendamustine-Polatuzumab-Rituximab

Description
Chemotherapy Protocol LYMPHOMA BENDAMUSTINE-POLATUZUMAB-RITUXIMAB Regimen • Lymphoma – Bendamustine-Polatuzumab-Rituximab Indication • Histologically diagnosed diffuse large B cell lymphoma (DLBCL) i
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Bendamustine-Polatuzumab-Rituximab.pdf

InP- VTD-PACE (IV) Bortezomib (IV) Cisplatin Cyclophosphamide Dexamethasone Doxorubicin Etoposide Thalidomide

Description
Chemotherapy Protocol MULTIPLE MYELOMA VTD-PACE (IV)-BORTEZOMIB (IV)-CISPLATIN-CYCLOPHOSPHAMIDEDEXAMETHASONE-DOXORUBICIN-ETOPOSIDE-TH
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/InP-VTD-PACE-IV-Bortezomib-IV-Cisplatin-Cyclophosphamide-Dexamethasone-Doxorubicin-Etoposide-Thalidomide.pdf

InP- VTD PACE (SC) Bortezomib (SC) Cisplatin Cyclophosphamide Dexamethasone Doxorubicin Etoposide Thalidomide

Description
Chemotherapy Protocol MULTIPLE MYELOMA VTD-PACE (SC)-BORTEZOMIB (SC)-CISPLATIN-CYCLOPHOSPHAMIDEDEXAMETHASONE-DOXORUBICIN-ETOPOSIDE-TH
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/InP-VTD-PACE-SC-Bortezomib-SC-Cisplatin-Cyclophosphamide-Dexamethasone-Doxorubicin-Etoposide-Thalidomide.pdf

Pembrolizumab_400mg skin

Description
Chemotherapy Protocol SKIN CANCER Pembrolizumab (400mg) Regimen • Skin – Pembrolizumab (400mg) Indication • Pembrolizumab is recommended; - as an option f
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Pembrolizumab-400mg.pdf

Pembrolizumab_200mg skin

Description
Regimen Chemotherapy Protocol SKIN CANCER Pembrolizumab (200mg) • Skin – Pembrolizumab (200mg) Indication • Pembrolizumab is recommended; - as an option f
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Pembrolizumab-200mg.pdf

Pembrolizumab Ver 1 skin

Description
Chemotherapy Protocol SKIN CANCER Pembrolizumab Pembrolizumab is currently available on a compassionate use basis only – not yet licensed in the UK
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinPembrolizumabVer1.pdf
391 to 400 of 555
Previous … 38 39 40 41 42 … Next